Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Bellmunt, 2017, A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now, Cancer Treat Rev, 54, 58, 10.1016/j.ctrv.2017.01.007 Powles, 2019, Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial, Nat Med, 25, 1706, 10.1038/s41591-019-0628-7 Necchi, 2018, Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study, J Clin Oncol, 36, 3353, 10.1200/JCO.18.01148 Bandini, 2020, Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study, Ann Oncol, 31, 1755, 10.1016/j.annonc.2020.09.011 van Dijk, 2020, Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial, Nat Med, 26, 1839, 10.1038/s41591-020-1085-z Gao, 2020, Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma, Nat Med, 26, 1845, 10.1038/s41591-020-1086-y Dindo, 2004, Classification of surgical complications, Ann Surg, 240, 205, 10.1097/01.sla.0000133083.54934.ae Gao, 2019, A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC), J Clin Oncol, 37, 4551, 10.1200/JCO.2019.37.15_suppl.4551 Carthon, 2010, Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial, Clin Cancer Res, 16, 2861, 10.1158/1078-0432.CCR-10-0569 Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, New Engl J Med, 349, 859, 10.1056/NEJMoa022148 Powles, 2018, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 391, 748, 10.1016/S0140-6736(17)33297-X Hussain, 2020, IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC), J Clin Oncol, 38, 5000, 10.1200/JCO.2020.38.15_suppl.5000 EORTC Genito-Urinary Group, 1999, Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, Lancet, 354, 533, 10.1016/S0140-6736(99)02292-8 Sathianathen, 2018, A simplified frailty index to predict outcomes after radical cystectomy, Eur Urol Focus, 5, 658, 10.1016/j.euf.2017.12.011 Kates, 2015, Frailty as a marker of adverse outcomes during cystectomy for urothelial cancer, J Clin Oncol, 33, 374, 10.1200/jco.2015.33.7_suppl.374 Michalik, 2020, Geriatric assessment among elderly patients undergoing urological surgery: a systematic literature review, Adv Clin Exp Med, 29, 399, 10.17219/acem/115085 Wildiers, 2014, International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer, J Clin Oncol, 32, 2595, 10.1200/JCO.2013.54.8347 Goldspink, 2005, Ageing and activity: their effects on the functional reserve capacities of the heart and vascular smooth and skeletal muscles, Ergonomics, 48, 1334, 10.1080/00140130500101247 Psutka, 2018, Staging the host: personalizing risk assessment for radical cystectomy patients, Eur Urol Oncol, 1, 292, 10.1016/j.euo.2018.05.010 Gao, 2018, A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.e16524 Grande, 2020, DUTRENEO trial: a randomized phase II trial of durvalumab and tremelimumab versus chemotherapy as a neoadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature, J Clin Oncol, 38, 5012, 10.1200/JCO.2020.38.15_suppl.5012 Hoimes, 2018, A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC), Ann Oncol, 29, viii726, 10.1093/annonc/mdy424.039 Gupta, 2020, Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy, J Clin Oncol, 38, 439, 10.1200/JCO.2020.38.6_suppl.439 Milenkovic, 2019, Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy, World J Urol, 37, 1857, 10.1007/s00345-018-2584-0 Necchi, 2019, Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies, Eur Urol, 77, 439, 10.1016/j.eururo.2019.10.026 Powles, 2019, J Clin Oncol, 37, TPS4592, 10.1200/JCO.2019.37.15_suppl.TPS4592 Siefker-Radtke, 2020, Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866, J Clin Oncol, 38, TPS599, 10.1200/JCO.2020.38.6_suppl.TPS599 Sonpavde, 2019, A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC), J Clin Oncol, 37, TPS4587, 10.1200/JCO.2019.37.15_suppl.TPS4587